Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer

Real-world data from a retrospective study of patients with metastatic HER2-positive breast cancer—presented during the 2023 ASCO Annual Meeting—showed that a higher proportion of patients receiving tucatinib-based therapy had brain metastases compared with the HER2CLIMB patient population. Further, tucatinib-based therapy in the real world is associated with a similar time to next treatment and time to discontinuation to PFS as observed in HER2CLIMB, including among a cohort of patients who received tucatinib following T-DXd therapy.